Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures

Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells

(2017) T H Dovmark et al.   ONCOGENE

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice

(2017) Yongchuan Gu et al.   Frontiers in Pharmacology

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy

(2016) Alexandra M. Mowday et al.   BIOCHEMICAL PHARMACOLOGY

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

(2016) Yusuke Ogitani et al.   CANCER SCIENCE

Quantitative characterization of in vitro bystander effect of antibody-drug conjugates

(2016) Aman P. Singh et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Monitoring the effects of doxorubicin on 3D-spheroid tumor cells in real-time

(2016) NamHuk Baek et al.   OncoTargets and Therapy

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs

(2015) F. W. Hunter et al.   CANCER RESEARCH

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

(2015) M. Konopleva et al.   HAEMATOLOGICA

Pan-cancer analysis of the extent and consequences of intratumor heterogeneity

(2015) Noemi Andor et al.   NATURE MEDICINE

Inhibition of Lysyl Oxidases Improves Drug Diffusion and Increases Efficacy of Cytotoxic Treatment in 3D Tumor Models

(2015) Friedrich Schütze et al.   Scientific Reports

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

(2015) M. Konopleva et al.   HAEMATOLOGICA

Tumor-Selective, Futile Redox Cycle-Induced Bystander Effects Elicited by NQO1 Bioactivatable Radiosensitizing Drugs in Triple-Negative Breast Cancers

(2014) Lifen Cao et al.   ANTIOXIDANTS & REDOX SIGNALING

Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5

(2014) Jingli Wang et al.   BIOCHEMICAL PHARMACOLOGY

Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion

(2014) A. V. Kalra et al.   CANCER RESEARCH

FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells

(2013) Jiechuang Su et al.   BIOCHEMICAL JOURNAL

High-resolution deep imaging of live cellular spheroids with light-sheet-based fluorescence microscopy

(2013) Francesco Pampaloni et al.   CELL AND TISSUE RESEARCH

Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence

(2013) Jiechuang Su et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumour heterogeneity in the clinic

(2013) Philippe L. Bedard et al.   NATURE

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling

(2013) Annika Foehrenbacher et al.   Frontiers in Oncology

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104

(2013) Annika Foehrenbacher et al.   Frontiers in Oncology

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

(2012) Mark J McKeage et al.   BMC CANCER

Targeted drug delivery for cancer therapy: the other side of antibodies

(2012) Michael A Firer et al.   Journal of Hematology & Oncology

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

(2012) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

(2011) F. Meng et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors

(2010) K. O. Hicks et al.   CLINICAL CANCER RESEARCH

Multicellular tumor spheroids: An underestimated tool is catching up again

(2010) Franziska Hirschhaeuser et al.   JOURNAL OF BIOTECHNOLOGY

DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity

(2009) R. S. Singleton et al.   CANCER RESEARCH